Dexpramipexole dihydrochloride is under clinical development by Areteia Therapeutics and currently in Phase II for Hypereosinophilic Syndrome. According to GlobalData, Phase II drugs for Hypereosinophilic Syndrome have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dexpramipexole dihydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dexpramipexole dihydrochloride overview
Dexpramipexole dihydrochloride (BIIB050, KNS760704) is under development for the treatment of hypereosinophilic syndrome and eosinophilic asthma . The drug candidate is formulated as film coated tablet and administered through oral route. BIIB050 is the chirally pure form of dexpramipexole. It was also under development for amyotrophic lateral sclerosis (ALS) and chronic rhinosinusitis.
Areteia Therapeutics overview
Areteia Therapeutics is a biotechnology company developing dexpramipexole, an oral medicine that inhibits the maturation of eosinophils. Areteia Therapeutics is headquartered in Bernardsville, New Jersey, the US.
For a complete picture of Dexpramipexole dihydrochloride’s drug-specific PTSR and LoA scores, buy the report here.